## Sara Corvigno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/219074/publications.pdf

Version: 2024-02-01

25 papers 448 citations

932766 10 h-index 19 g-index

26 all docs

26 docs citations

times ranked

26

869 citing authors

#	Article	IF	CITATIONS
1	Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 803.	1.2	5
2	Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Reports, 2022, 38, 110301.	2.9	4
3	Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. IScience, 2022, 25, 103923.	1.9	23
4	Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Molecular Cancer Therapeutics, 2022, , .	1.9	5
5	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269.	2.7	25
6	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. Lung Cancer, 2021, 155, 10-19.	0.9	28
7	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3545-3555.	1.2	5
8	Plateletâ€derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. Glia, 2020, 68, 979-988.	2.5	4
9	Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers. PLoS ONE, 2020, 15, e0236291.	1.1	10
10	Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer. Molecular Cancer Therapeutics, 2020, 19, 1943-1954.	1.9	5
11	Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor. Advances in Therapy, 2020, 37, 5023-5031.	1.3	6
12	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. Gynecologic Oncology, 2020, 159, 860-868.	0.6	4
13	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238.	1.7	13
14	Adaptive RSKâ€EphA2â€GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO Molecular Medicine, 2020, 12, e11177.	3.3	39
15	Title is missing!. , 2020, 15, e0236291.		O
16	Title is missing!. , 2020, 15, e0236291.		0
17	Title is missing!. , 2020, 15, e0236291.		O
18	Title is missing!. , 2020, 15, e0236291.		0

#	Article	IF	CITATIONS
19	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports, 2019, 9, 17589.	1.6	12
20	Microvascular Mural Cells in Cancer. Trends in Cancer, 2018, 4, 838-848.	3.8	16
21	Perivascular PDGFR- $\hat{l}^2$ is an independent marker for prognosis in renal cell carcinoma. British Journal of Cancer, 2017, 116, 195-201.	2.9	33
22	Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. Nature Biomedical Engineering, 2017, 1, 796-806.	11.6	131
23	Multiâ€parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumourâ€typeâ€specific stroma phenotypes and a novel vascular biomarker. Journal of Pathology: Clinical Research, 2017, 3, 214-224.	1.3	8
24	Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. Oncotarget, 2016, 7, 18573-18584.	0.8	40
25	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget, 0, 7, 41948-41958.	0.8	30